SOCMA Lends Support for Measures Addressing Nontariff Barriers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Lends Support for Measures Addressing Nontariff Barriers


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) issued a statement to support a recently introduced bill intended to help the federal government deal with market-access barriers more effectively. The bill, HR 3112, the Trade Law Enforcement Act, was introduced by Rep. Michael Turner (R-OH) on Oct. 6, 2011. The bill would formalize the process by which the Office of the United States Trade Representative (USTR) acts on market-access barriers that are deemed unlawful under US trade agreements.

“This bill elevates a process already in place for companies to report the unfair practices they are experiencing for investigation,” said SOCMA in a Nov. 3, 2011, press statement. “Formalizing the process allows companies to understand the resources that exist within the government, which often they do not know exist. In a time when businesses are looking more at new opportunities to export abroad to growing markets, having a resource such as this to ensure that companies can take full advantage of opportunities and agreements we have in place is extremely important.”

Under current law, the USTR has the ability to respond to various trade practices deemed unfair, including market-access problems caused by nontariff barriers. SOCMA says that while US manufacturers can petition the USTR to take action, they seldom do, partly because of the cost of compiling an adequate petition and the uncertainty of getting timely relief.

SOCMA is urging other members of Congress to show their support for the legislation. SOCMA is the US-based trade association representing custom and batch manufacturers, including producers of fine chemicals, pharmaceutical intermediates, and APIs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here